GR1007832B - Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" - Google Patents
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"Info
- Publication number
- GR1007832B GR1007832B GR20110100649A GR20110100649A GR1007832B GR 1007832 B GR1007832 B GR 1007832B GR 20110100649 A GR20110100649 A GR 20110100649A GR 20110100649 A GR20110100649 A GR 20110100649A GR 1007832 B GR1007832 B GR 1007832B
- Authority
- GR
- Greece
- Prior art keywords
- activin
- aberrant
- activation
- diseases
- host defence
- Prior art date
Links
- 108010059616 Activins Proteins 0.000 title abstract 4
- 102000005606 Activins Human genes 0.000 title abstract 4
- 239000000488 activin Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000001594 aberrant effect Effects 0.000 title abstract 3
- 230000004913 activation Effects 0.000 title abstract 3
- 230000004665 defense response Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 102000018918 Activin Receptors Human genes 0.000 abstract 1
- 108010052946 Activin Receptors Proteins 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 102000053642 Catalytic RNA Human genes 0.000 abstract 1
- 108090000994 Catalytic RNA Proteins 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 102100020921 Follistatin Human genes 0.000 abstract 1
- 108010014612 Follistatin Proteins 0.000 abstract 1
- 102100029379 Follistatin-related protein 3 Human genes 0.000 abstract 1
- 101001062529 Homo sapiens Follistatin-related protein 3 Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 108010023082 activin A Proteins 0.000 abstract 1
- 108010023079 activin B Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108091092562 ribozyme Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα ευρεσιτεχνία αφορά σε μεθόδους και συνθέσεις για χρήση στην Ιατρική και παρεμφερείς επιστήμες, των αδρανοποιητών της ακτιβίνης, ή μείγματος αυτών, για την κατασκευή φαρμάκου για την προφύλαξη ή/και θεραπεία ασθενειών που σχετίζονται με παρεκκλίνουσα ενεργοποίηση της αμυντικής απόκρισης του ξενιστή [aberrant "Host Defence Response"] σε ένα υποκείμενο. Η παρούσα ευρεσιτεχνία παρέχει αδρανοποιητές της ακτιβίνης, με την μορφή διαλυτών ActRII πολυπεπτιδίων ή τμήματος ή ανάλογων αυτών, την φολλιστατίνη και την πρωτεΐνη follistatin-like 3 ή τμήματος ή ανάλογων αυτών, μικρού μοριακού βάρους οργανικές ενώσεις, αντισώματα έναντι είτε της ακτιβίνης-Α, ακτιβίνης-Β, ή των υποδοχέων των ακτιβινών ή ανοσογόνων τμημάτων αυτών, αντιπληροφοριακά νουκλεϊκά οξέα, ριβόζυμα, φορείς τριπλής αλύσου, siRNAs και miRNAs. Επίσης παρέχονται φαρμακευτικές συνθέσεις, που περιλαμβάνουν μια θεραπευτικά ή προφυλακτικά αποτελεσματική ποσότητα τουλάχιστον ενός αδρανοποιητή της ακτιβίνης αναμεμιγμένο με φαρμακευτικά αποδεκτούς φορείς, πρόσθετα ή/και διαλύτες. Επίσης παρέχονται μέθοδοι για την προφύλαξη ή/και θεραπεία ασθενειών (συμπεριλαμβάνοντας συνδυασμούς θεραπειών) που σχετίζονται με αναφερόμενη παρεκκλίνουσα ενεργοποίηση της αμυντικής απόκρισης του ξενιστή [aberrant "Host Defence Response"]. Στις ασθένειες που μπορούν να αντιμετωπιστούν σύμφωνα με τις μεθόδους της παρούσας ευρεσιτεχνίας περιλαμβάνονται η οξεία πνευμονική βλάβη/οξεία αναπνευστική δυσπραγία, ή σήψη και η χρόνια αποφρακτική πνευμονοπάθεια.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20110100649A GR1007832B (el) | 2011-11-21 | 2011-11-21 | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| EP12007751.6A EP2594280A1 (en) | 2011-11-21 | 2012-11-16 | Activin neutralisers and uses thereof for treatment of diseases associated with aberrant "host defence response" activation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20110100649A GR1007832B (el) | 2011-11-21 | 2011-11-21 | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1007832B true GR1007832B (el) | 2013-02-14 |
Family
ID=47178449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20110100649A GR1007832B (el) | 2011-11-21 | 2011-11-21 | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2594280A1 (el) |
| GR (1) | GR1007832B (el) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109922821A (zh) * | 2016-10-20 | 2019-06-21 | 马萨诸塞州渤健公司 | 使用新型杂合actriib配体陷阱蛋白治疗肌肉萎缩和骨病的方法 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2016090035A2 (en) * | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| CN107428818A (zh) | 2015-01-29 | 2017-12-01 | 密西根州立大学校董会 | 隐藏多肽及其用途 |
| WO2016130814A1 (en) * | 2015-02-11 | 2016-08-18 | The Trustees Of Columbia University In The City Of New York | Inhibitors of induced mmp-1 production |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| AU2017222526A1 (en) * | 2016-02-22 | 2018-08-23 | Acceleron Pharma Inc. | ActRII antagonists for use in increasing immune activity |
| HRP20210694T1 (hr) | 2016-07-15 | 2021-09-17 | Acceleron Pharma, Inc. | Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije |
| CN110430890B (zh) | 2016-11-10 | 2024-09-10 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| CN111787981B (zh) | 2018-03-01 | 2025-12-30 | 瑞泽恩制药公司 | 增加肌肉量和减少脂肪量的方法 |
| JP7405772B2 (ja) | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| AU2020284038A1 (en) * | 2019-05-30 | 2021-12-02 | Acceleron Pharma Inc. | ActRII-binding proteins and uses thereof |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| EP4142769A4 (en) | 2020-04-28 | 2024-05-15 | Acceleron Pharma Inc. | ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010364A1 (en) * | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| WO2003006057A1 (en) * | 2001-07-13 | 2003-01-23 | Bioa Pty Limited | Composition and method for the treatment of disease |
| WO2005032578A1 (en) * | 2003-10-06 | 2005-04-14 | Monash University | Therapeutic method |
| WO2006012627A2 (en) * | 2004-07-23 | 2006-02-02 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| WO2006083182A1 (en) * | 2005-02-07 | 2006-08-10 | Orico Limited | Use of myostatin (gdf-8) antagonists for improving wound healing and preventing fibrotic disease |
| WO2009158015A2 (en) * | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| JP2004521915A (ja) | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Ｔｇｆ過剰発現に対するピラゾール誘導体 |
-
2011
- 2011-11-21 GR GR20110100649A patent/GR1007832B/el active IP Right Grant
-
2012
- 2012-11-16 EP EP12007751.6A patent/EP2594280A1/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010364A1 (en) * | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| WO2003006057A1 (en) * | 2001-07-13 | 2003-01-23 | Bioa Pty Limited | Composition and method for the treatment of disease |
| WO2005032578A1 (en) * | 2003-10-06 | 2005-04-14 | Monash University | Therapeutic method |
| WO2006012627A2 (en) * | 2004-07-23 | 2006-02-02 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| WO2006083182A1 (en) * | 2005-02-07 | 2006-08-10 | Orico Limited | Use of myostatin (gdf-8) antagonists for improving wound healing and preventing fibrotic disease |
| WO2009158015A2 (en) * | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
Non-Patent Citations (4)
| Title |
|---|
| CHEN Y ET AL: "Follistatin, An Activin A Binding Protein, Reduces Infarct Size in Myocardial Ischaemia Reperfusion Injury", HEART, LUNG AND CIRCULATION, ELSEVIER, AMSTERDAM, NL, vol. 20, no. 1, 1 January 2011 (2011-01-01), pages 36, XP027599519, ISSN: 1443-9506, [retrieved on 20110101], DOI: 10.1016/J.HLC.2010.10.008 * |
| HARRISON C A ET AL: "Antagonists of activin signaling: mechanisms and potential biological applications", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 16, no. 2, 1 March 2005 (2005-03-01), pages 73 - 78, XP027790070, ISSN: 1043-2760, [retrieved on 20050301] * |
| PHILLIPS D J ET AL: "Activin and related proteins in inflammation: Not just interested bystanders", CYTOKINE AND GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 20, no. 2, 1 April 2009 (2009-04-01), pages 153 - 164, XP026036635, ISSN: 1359-6101, [retrieved on 20090303], DOI: 10.1016/J.CYTOGFR.2009.02.007 * |
| WERNER S ET AL: "Roles of activin in tissue repair, fibrosis, and inflammatory disease", CYTOKINE AND GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 17, no. 3, 1 June 2006 (2006-06-01), pages 157 - 171, XP024987977, ISSN: 1359-6101, [retrieved on 20060601], DOI: 10.1016/J.CYTOGFR.2006.01.001 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109922821A (zh) * | 2016-10-20 | 2019-06-21 | 马萨诸塞州渤健公司 | 使用新型杂合actriib配体陷阱蛋白治疗肌肉萎缩和骨病的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2594280A1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| MX348817B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| MX359548B (es) | Agentes de iarn modificados. | |
| JP2015517488A5 (el) | ||
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MX359989B (es) | Fármacos antivirales para el tratamiento de la infección por arenavirus. | |
| NZ625391A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| WO2009123776A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| JP2015518818A5 (el) | ||
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| RU2739037C3 (ru) | Композиция для контролируемой стимуляции яичников | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| WO2012170918A3 (en) | Methods of treatment for retinal diseases | |
| EP1758998A4 (en) | OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| WO2016033432A9 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| JP2013520447A5 (el) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted |
Effective date: 20130327 |